Lyell Immunopharma Inc

NASDAQ:LYELUnited States

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.

Contact Information

Headquarters

201 Haskins Way, Suite 301SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-695-0677

Fax

302-531-3150

Executives

Chairman of the Board

Richard Klausner

President, Chief Executive Officer, Director

Lynn Seely

Chief Financial Officer

Charles Newton

Chief Operating Officer

Stephen Hill

Chief Scientific Officer

Gary Lee